Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 4 publications
Immune persistence and safety of the AS01E-adjuvanted respiratory syncytial virus prefusion F protein-based vaccine in adults 50-59 years of age, including at-increased-risk adults: A randomized controlled trial.
Journal: Human vaccines & immunotherapeutics
Published: November 06, 2025
Long-Term Safety of Epicutaneous Immunotherapy in Peanut-Allergic Children: An Open-Label Active Treatment (REALISE Study).
Journal: The journal of allergy and clinical immunology. In practice
Published: August 13, 2024
Noninferior Immunogenicity and Consistent Safety of Respiratory Syncytial Virus Prefusion F Protein Vaccine in Adults 50-59 Years Compared to ≥60 Years of Age.
Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Published: February 29, 2024
Safety of Epicutaneous Immunotherapy in Peanut-Allergic Children: REALISE Randomized Clinical Trial Results.
Journal: The journal of allergy and clinical immunology. In practice
Published: July 09, 2021
Showing 1-4 of 4
Last Updated: 09/26/2026